Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape

• Published in: Journal of thoracic oncology 2017-06, Vol.12 (6), p.943-953
• Main Authors: Faruki, Hawazin, Mayhew, Gregory M., Serody, Jonathan S., Hayes, D. Neil, Perou, Charles M., Lai-Goldman, Myla
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - classification; Adenocarcinoma - genetics; Adenocarcinoma - immunology; Adenocarcinoma - pathology; B7-H1 Antigen - metabolism; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Carcinoma, Non-Small-Cell Lung - classification; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Squamous Cell - classification; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - immunology; Carcinoma, Squamous Cell - pathology; CTLA-4 Antigen - metabolism; Gene expression; Humans; Immune response; Lung cancer; Lung Neoplasms - classification; Lung Neoplasms - genetics; Lung Neoplasms - immunology; Lung Neoplasms - pathology; PD-L1; Prognosis; Squamous cell carcinoma; Survival Rate; T-Lymphocytes - immunology; Tumor Microenvironment - genetics; Tumor Microenvironment - immunology
• ISSN: 1556-0864; 1556-1380
• DOI: 10.1016/j.jtho.2017.03.010

Molecular subtyping of lung adenocarcinoma (AD) and lung squamous cell carcinoma (SCC) reveal biologically diverse tumors that vary in their genomic and clinical attributes. Published immune cell signatures and several lung AD and SCC gene expression data sets, including The Cancer Genome Atlas, were used to examine immune response in relation to AD and SCC expression subtypes. Expression of immune cell populations and other immune related genes, including CD274 molecule gene (CD274) (programmed death ligand 1), was investigated in the tumor microenvironment relative to the expression subtypes of the AD (terminal respiratory unit, proximal proliferative, and proximal inflammatory) and SCC (primitive, classical, secretory, and basal) subtypes. Lung AD and SCC expression subtypes demonstrated significant differences in tumor immune landscape. The proximal proliferative subtype of AD demonstrated low immune cell expression among ADs whereas the secretory subtype showed elevated immune cell expression among SCCs. Tumor expression subtype was a better predictor of immune cell expression than CD274 (programmed death ligand 1) in SCC tumors but was a comparable predictor in AD tumors. Nonsilent mutation burden was not correlated with immune cell expression across subtypes; however, major histocompatibility complex class II gene expression was highly correlated with immune cell expression. Increased immune and major histocompatibility complex II gene expression was associated with improved survival in the terminal respiratory unit and proximal inflammatory subtypes of AD and in the primitive subtype of SCC. Molecular expression subtypes of lung AD and SCC demonstrate key and reproducible differences in immune host response. Evaluation of tumor expression subtypes as potential biomarkers for immunotherapy should be investigated.